PLX5622 (C09-1017-317)

InformationPLX5622 PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.TargetsCSF-1R (Cell-free assay); FLT3 (Cell-free assay); KIT (Cell-free assay); AURKC (Cell-free assay); KDR (Cell-free assay);0.016 μM; 0.39 μM; 0.86 μM; 1 μM; 1.1 μMIn vivoIn vivo PLX5622 demonstrates desirable PK properties in mice, rats, dogs, and monkeys, with a brain penetrance of ~20%. PLX5622 has low systemic clearance, moderate volume of distribution, and favorable oral bioavailability (F > 30%) in all four species. PLX5622 is a useful compound for investigating microglial dynamics. It allows for the sustained and specific elimination of microglia, preceding and during pathology development of Alzheimer’s disease (AD). Long-term PLX5622-mediated microglial depletion is highly robust, sustainable, and specific to the microglial compartment. Specification: 0.98 Molecular Formula: C21H19F2N5O Molecular Weight: 395.41 PubChem CID: 52936034 Isomeric SMILES: CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1 Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/P414234-SCI_7a79df458bb9edb2f68e920e7e938c95.pdf